Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.

Hifumi, Toru; Isokawa, Shutaro; Otani, Norio; Ishimatsu, Shinichi

Hifumi, Toru; Isokawa, Shutaro; Otani, Norio; Ishimatsu, Shinichi.

Hifumi T; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. hifumitoru@gmail.com.
Isokawa S; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Otani N; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Ishimatsu S; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.

Crit Care ; 24(1): 497, 2020 08 12.

Article in English | MEDLINE | ID: covidwho-713498

Subject(s)

Coronavirus Infections; Critical Illness; Pandemics; Pneumonia, Viral; Amides; Benzamidines; Betacoronavirus; COVID-19; Guanidines; Humans; Pyrazines; SARS-CoV-2

Keywords

Adverse events; COVID-19; Favipiravir; Nafamostat mesylate

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Critical Illness / Coronavirus Infections / Pandemics Limits: Humans Language: English Journal: Crit Care Year: 2020 Document Type: Article Affiliation country: S13054-020-03227-4

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google